{"story":{"id":1607128,"title":"Targeting IL-33 in COPD: Who Benefits and What Remains Unknown - HCPLive","permalink":"https://checknews.org/historia.php?id=1607128","status":"quiet","category":"science","country":"IN","country_name":"India","language":"en","first_seen_at":"2026-11-07T15:44:22-06:00","last_activity_at":"2026-11-07T15:44:22-06:00","source_count":1,"article_count":1,"image":"https://checknews.org/media/img/2026/11/1607128.jpg","articles":[{"title":"Targeting IL-33 in COPD: Who Benefits and What Remains Unknown - HCPLive","publisher":"HCPLive","url":"https://www.hcplive.com/view/targeting-il-33-copd-who-benefits-what-remains-unknown-","country":"IN","country_name":"India","language":"en","published_at":"2026-11-07T15:44:22-06:00"}],"source_url":"https://www.hcplive.com/view/targeting-il-33-copd-who-benefits-what-remains-unknown-","publishers":[{"name":"HCPLive","country":"IN","country_name":"India"}],"countries":["IN"]},"generated_at":"2026-11-15T00:20:25-06:00"}